Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 113.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,417,152 shares of the biopharmaceutical company's stock after purchasing an additional 753,060 shares during the period. Squarepoint Ops LLC owned about 0.47% of Amicus Therapeutics worth $13,350,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in FOLD. Covestor Ltd boosted its stake in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 2,312 shares during the period. R Squared Ltd acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $79,000. KBC Group NV grew its stake in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $100,000. Finally, Stephens Inc. AR acquired a new stake in shares of Amicus Therapeutics in the 4th quarter worth $101,000.

Amicus Therapeutics Price Performance

Shares of FOLD stock traded up $0.04 during mid-day trading on Tuesday, reaching $6.26. The stock had a trading volume of 2,591,927 shares, compared to its average volume of 3,350,180. The company has a market cap of $1.93 billion, a P/E ratio of -34.72, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12-month low of $5.81 and a 12-month high of $12.65. The business has a 50-day simple moving average of $7.05 and a 200 day simple moving average of $8.68.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. UBS Group increased their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company reduced their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.